+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Doxorubicin"

From
Doxorubicin - Global Strategic Business Report - Product Thumbnail Image

Doxorubicin - Global Strategic Business Report

  • Report
  • March 2025
  • 288 Pages
  • Global
From
Doxorubicin Market Report 2025 - Product Thumbnail Image

Doxorubicin Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Doxorubicin Market 2024-2028 - Product Thumbnail Image

Doxorubicin Market 2024-2028

  • Report
  • August 2024
  • 163 Pages
  • Global
From
From
From
From
Liposomal Doxorubicin Global Market Report 2024 - Product Thumbnail Image

Liposomal Doxorubicin Global Market Report 2024

  • Report
  • August 2024
  • 175 Pages
  • Global
From
From
Gastric Cancer Drugs Market Report 2025 - Product Thumbnail Image

Gastric Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Ovarian Cancer Drugs Market Report 2025 - Product Thumbnail Image

Ovarian Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Gynecological Cancer Drugs Market Report 2025 - Product Thumbnail Image

Gynecological Cancer Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Loading Indicator

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more